Inhibición “Dual” de Endotelio & Pericitos
120
100
80
60
40
20
0
10 12 13.5 13.5 16
16
Regression trial
Intervention trial
Tumour burden (mm
3
)
Week
Control (PBS)
SU5416 + SU6668
(VEGFRi+PDGFRi)
SU5416 + imatinib
(VEGFRi+PDGFRi)
Survival
100
80
60
40
20
0
Percent survival
Time (weeks of age)
Control arm
Sunitinib arm
p=1.17x10
-8
10 12 14 16 18 20 22 24 26
Pietras K & Hanahan D.
J Clin Oncol
2005
;
Casanovas O, et al.
Cancer Cell
2005
